UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Leukemia & lymphoma, ISSN 1042-8194, 2009, Volume 50, Issue 8, pp. 1257 - 1260
chemotherapeutic approaches | Lymphoma and Hodgkin disease | prognostication | Hodgkin Disease - diagnostic imaging | Severity of Illness Index | Radiopharmaceuticals - pharmacokinetics | Lymphoma - diagnostic imaging | Humans | Positron-Emission Tomography - methods | Tissue Distribution | Validation Studies as Topic | Sensitivity and Specificity | Positron-Emission Tomography - standards | Lymphoma, B-Cell - diagnostic imaging | Retrospective Studies | Observer Variation | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Evidence-based medicine | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Index Medicus | Abridged Index Medicus | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Age Factors | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Time Factors | Aged, 80 and over | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Rituximab | Treatment Outcome | Chi-Square Distribution | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Medical research | Anthracyclines | Corticosteroids | Medicine, Experimental | Aged patients | Lymphomas | Product development | Comparative analysis | Standards | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Rituximab | Male | Antineoplastic Agents - therapeutic use | Tumor Burden | Remission Induction | Disease Progression | Young Adult | Aged, 80 and over | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Chemotherapy | Lymphomas | Drug therapy | Health aspects | Cancer | Studies | Stock options | Educational materials | Cancer therapies | Cervical cancer | Tropical diseases | Skin cancer | Index Medicus | Abridged Index Medicus | Side effects | infection | lymphoma | survival | clinical trials | Maintenance | intervention | chemotherapy
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 9, pp. 1182 - 1189
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Aminopterin - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Prospective Studies | Standard of Care | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Treatment Outcome | Remission Induction | Folic Acid Antagonists - therapeutic use | Neoplasm Recurrence, Local - pathology | Young Adult | International Agencies | Lymphoma, T-Cell, Peripheral - pathology | Aged, 80 and over | Adult | Female | Aged | Aminopterin - analogs & derivatives | Drug Resistance, Neoplasm - drug effects | Index Medicus | Original Reports | Hema13
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2912 - 2919
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Antibodies, Monoclonal, Humanized - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Male | Antineoplastic Agents - administration & dosage | Lymphoma, Large B-Cell, Diffuse - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Lymphoma, Mantle-Cell - metabolism | Index Medicus | Life Sciences
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2019, Volume 20, Issue 7, pp. 998 - 1010
Journal Article
European journal of nuclear medicine and molecular imaging, ISSN 1619-7070, 11/2014, Volume 41, Issue 11, pp. 2017 - 2022
Medicine & Public Health | Total lesion glycolysis | Orthopedics | PET/CT | Oncology | Nuclear Medicine | Imaging / Radiology | Cardiology | Outcome prediction | Diffuse large B-cell lymphoma | Metabolic tumour volume | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Multivariate Analysis | Reproducibility of Results | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Positron-Emission Tomography | Lymphoma, Large B-Cell, Diffuse - metabolism | Tumor Burden | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Lymphoma, Large B-Cell, Diffuse - therapy | Aged, 80 and over | Adult | Female | Fluorodeoxyglucose F18 | Aged | Glucose metabolism | Care and treatment | Lymphomas | PET imaging | Patient outcomes | Tomography | Nuclear medicine | Lymphoma | Immunotherapy | Tumors | Index Medicus | Life Sciences
Journal Article
Nature genetics, ISSN 1061-4036, 2014, Volume 46, Issue 4, pp. 329 - 335
Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | Immunohistochemistry | Phosphorylation | Mediastinal Neoplasms - genetics | Hodgkin Disease - genetics | Hodgkin Disease - pathology | Humans | Kaplan-Meier Estimate | Laser Capture Microdissection | Gene Expression Profiling - methods | In Situ Hybridization, Fluorescence | Lymphoma, B-Cell - genetics | Mutation - genetics | Gene Knockdown Techniques | RNA Interference | Mediastinal Neoplasms - pathology | HEK293 Cells | Lymphoma, B-Cell - pathology | High-Throughput Nucleotide Sequencing | Protein Tyrosine Phosphatase, Non-Receptor Type 1 - genetics | Genomics - methods | Real-Time Polymerase Chain Reaction | Gene mutations | Lymphomas | Genetic aspects | Nucleotide sequencing | Identification and classification | Methods | DNA sequencing | Medical research | Mutation | Kinases | Lymphoma | Index Medicus
Journal Article